NCT07548944Recruiting
Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance
Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation (TES) on Visual Performance in Patients With Retinitis Pigmentosa and Similar Retinal Diseases
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
Retinitis pigmentosa and similar degenerative diseases of the retina lead to progressive loss of vision. TES therapy with the CE-marked OkuStim® System is a treatment approved in the EU for slowing the progression of the disease. Patients increasingly report short-term subjective improvements in vision, which have not yet been systematically investigated. This exploratory study is conducted to determine whether these subjective short-term effects can be measured, and therefore also be quantified, by objective tests.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 13 Apr 2026
- Start date
- 20 Apr 2026
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- Okuvision GmbH
- Diseases
- Retinitis pigmentosa
- NCT number
- NCT07548944
What you commit to
- Study type: Observational
- Planned participants: 30
- From 20 Apr 2026 to the primary completion date, 31 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of other eye diseases (e.g., cataract, glaucoma, macular degeneration) that, in the opinion of the investigator, compromise or confound study assessments
Other
- Cognitive, psychological, or linguistic limitations that prevent informed consent or proper study participation
- Simultaneous participation in other clinical studies that could influence the results of the study
- Severe comorbidities that could compromise patient safety or study conduct
Who the study is looking for
- Adult patients (≥ 18 years) with clinically diagnosed retinitis pigmentosa (RP) or other similar degenerative retinal disease
- Current treatment with TES using the OkuStim® System within the intended purpose
- Subjective perception of short-term effects after TES treatment
- Ability and willingness to give informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Augenzentrum Frankfurt Prof. Koch GmbH Coordinator of this site? Confirm its status | Frankfurt am Main | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.